Novartis AG ADR (NVS)vsPACS Group, Inc. (PACS)
NVS
Novartis AG ADR
$140.98
+0.21%
HEALTHCARE · Cap: $260.70B
PACS
PACS Group, Inc.
$41.53
-1.26%
HEALTHCARE · Cap: $6.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 921% more annual revenue ($56.69B vs $5.55B). NVS leads profitability with a 22.5% profit margin vs 4.8%. PACS appears more attractively valued with a PEG of 1.06. PACS earns a higher WallStSmart Score of 58/100 (C).
NVS
Buy51
out of 100
Grade: C-
PACS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.98
$47.58 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 51.6% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
4.8% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PACS
The primary concerns for PACS are Profit Margin, Altman Z-Score, Debt/Equity. Debt-to-equity of 2.93 is elevated, increasing financial risk. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PACS is growing revenue faster at 9.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PACS scores higher overall (58/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across various sectors through innovative software and hardware systems. The company prioritizes research and development to leverage emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic collaborations and a solid market presence, PACS Group is well-positioned for sustainable growth, making it an attractive investment proposition for institutional investors seeking to participate in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?